Abstract
Although the number of studies using tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) for the treatment of high-risk pediatric solid tumors has been increasing, documentation of hematologic recovery after tandem HDCT/autoSCT is very limited. We retrospectively analyzed the hematologic recovery of 236 children with high-risk solid tumors who underwent tandem HDCT/autoSCT. The median numbers of CD34+ cells transplanted during the first and second HDCT/autoSCT were 4.3 × 10⁶/kg and 4.1 × 10⁶/kg, respectively (P = 0.664). While there was no difference in neutrophil recovery between the first and second HDCT/autoSCT, platelet and RBC recoveries were significantly delayed in the second HDCT/autoSCT (P < 0.001). Delayed recovery in the second HDCT/autoSCT was more prominent when the number of transplanted CD34+ cells was lower, especially if it was < 2 × 10⁶/kg. A lower CD34+ cell count was also associated with increased RBC transfusion requirements and higher serum ferritin levels. More CD34+ cells are required during the second HDCT/autoSCT to achieve the same hematologic recovery as the first.
Introduction
For children with high-risk solid tumors like neuroblastoma or certain brain cancers, standard chemotherapy often fails to prevent relapse. To improve survival rates, clinicians utilize "tandem" transplants: two sequential rounds of ultra-high-dose chemotherapy (HDCT), each followed by a "rescue" infusion of the patient’s own stored autologous stem cells (autoSCT). While this aggressive approach can improve outcomes, it puts immense strain on the bone marrow.
Data on hematologic recovery after the "second hit" in a tandem cycle is sparse. If the blood system takes too long to bounce back, patients face prolonged risks of life-threatening infections, bleeding, and long-term toxicities from repeated blood transfusions, such as iron overload. This study quantifies these delays and identifies the stem cell dose required for successful recovery.
Methods
A retrospective analysis was conducted on 236 children treated at Samsung Medical Center between 1998 and 2011. Primary diagnoses included neuroblastoma (49.6%), brain tumors (35.2%), and retinoblastoma (8.1%). Researchers tracked three primary markers of recovery: neutrophils (ANC > 500/µL), platelets (> 20,000/µL without transfusion), and red blood cells (Hemoglobin > 8.0 g/dL without transfusion). Patients were categorized by the number of CD34+ cells infused: Group A (> 5 × 10⁶/kg), Group B (2–5 × 10⁶/kg), and Group C (< 2 × 10⁶/kg). Multivariate Cox regression analysis was used to determine clinical factors independently affecting recovery times.
Results
The study found lineage-specific differences in recovery. Neutrophil recovery (ANC) was identical between the first and second rounds, with a median of 10 days (P = 0.167).
In contrast, platelet and RBC recoveries were significantly delayed in the second round. Platelet recovery took a median of 22 days in the first round versus 28 days in the second (P < 0.001). RBC recovery took 40 days in the first round versus 45 days in the second (P < 0.001).
A clear "threshold" effect was observed at 2 × 10⁶ CD34+ cells/kg. Patients below this threshold in the second round experienced a jump in RBC recovery time from 48 to 74 days. This delay increased transfusion burdens; patients in the low-dose group required significantly more platelet and RBC transfusions during the first year (P < 0.001). Consequently, one year after the second transplant, the low-dose group had median ferritin levels of 1,218 ng/mL, nearly double that of the mid-dose group (649 ng/mL), indicating secondary iron overload.
Discussion
The results suggest that the bone marrow microenvironment may be damaged by the first HDCT round, specifically hindering erythroid and megakaryocytic lineages. To achieve recovery speeds in the second round comparable to the first, a higher dose of CD34+ stem cells is necessary. For "poor mobilizers," agents like plerixafor should be considered to boost stem cell harvest. While this retrospective study identifies the delay, further research is needed to define the absolute optimal dose for the second transplant to minimize long-term complications like iron overload and the need for iron chelation therapy.
Summary updated